← Back to patent-cliff list
盐酸左西替利嗪/盐酸伪麻黄碱
Tier C — Watch / tradeLevocetirizine dihydrochloride/Pseudoephedrine Hydrochloride
韩美药品株式会社
Originator
2005
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：HRH1、α-adrenoceptors
Brand：Kossak2、Cossac L
Indications (approved)：鼻炎、过敏性鼻炎
Regional status
US
-
EU
-
China
批准上市
2005-12-30
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Levocetirizine dihydrochloride/Pseudoephedrine Hydrochloride?
Approved indications include: 鼻炎, 过敏性鼻炎.
When does the Levocetirizine dihydrochloride/Pseudoephedrine Hydrochloride patent expire?
No public expiry year is available for Levocetirizine dihydrochloride/Pseudoephedrine Hydrochloride yet; this page updates once verified.
How do I get a quote for Levocetirizine dihydrochloride/Pseudoephedrine Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24